Investmentfonds - News

Investmentfonds.de 17.07.2013:
DGAP-News: Geratherm Medical AG: Cooperation between Philips and apoplex provides substantial improvement in stroke care

DGAP-News: Geratherm Medical AG / Key word(s): Alliance
Geratherm Medical AG: Cooperation between Philips and apoplex provides
substantial improvement in stroke care

17.07.2013 / 09:55

---------------------------------------------------------------------


Corporate News

Together Against Stroke
Cooperation between Philips and apoplex medical provides substantial
improvement in stroke care

Hamburg / Pirmasens, July 17, 2013 - By automated merging of patient
information, apoplex medical technolo>gies and Philips will take the next
step in the battle against stroke. Particularly stroke patients with
strokes of unknown origin could benefit from this.

Undetected atrial fibrillation is considered to be a potential cause for
stroke. Several methods for the detection of paroxysmal atrial fibrillation
can help to confirm this assumption. With the fully automated ECG analysis
for the detection of atrial fibrillation SRAclinic (SRA = Stroke Risk
Analysis), developed by apoplex medical technologies, a method is now
available, which is significantly superior to all previous standard
methods.  The ECG data for this analysis are provided for example by the
patient monitoring system Philips IntelliVue. It records the patient data
at the stroke unit and exports them pseudonymized at the touch of a button
to the analysis server in the data center of apoplex medical technologies.
There the data are analysed for paroxysmal atrial fibrillation (pxVHF) and
summarized for the physician in a clearly arranged and expressive report.
Based on this, a therapy with anticoagulants can be initiated, which
reduces the risk for further strokes substantially.

'A retrospective output function, integrated in the Philips IntelliVue
Monitoring System, enables the transfer of up to 96 hours long term ECGs
without additional interface effort', explains Thomas Groß, Business
Manager Patient Monitoring at Philips Healthcare Germany. This simplifies
the clinical processes in a considerable extent. All stroke patients
connected to a Philips Monitoring System are examined for atrial
fibrillation during their complete bed time. There are no additional
activities, neither for the physicians nor for the nursing staff, which
could lead to further burden. As the data center of apoplex medical
technologies is available to all hospitals, there are no additional
technical requirements at the hospitals.

For Albert Hirtz, General Manager at apoplex medical technologies, it is
obvious that patients and the health system equally benefit from such
prevention: 'each prevented stroke is a piece of luck for the people. And
for the society it means a substantial reduction of costs in the end.' In
Germany 250.000 people suffer from stroke each year. In 35 to 40 percent of
these strokes, the origin is not detectable.
.

Further information to SRAclinic at: www.apoplexmedical.com

Further information to IntelliVue Patient Monitoring at: www.philips.de

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being
company, focused on improving people's lives through meaningful innovation
in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered
in the Netherlands, Philips posted 2012 sales of EUR 24.8 billion and
employs approximately 116,000 employees with sales and services in more
than 100 countries. The company is a leader in cardiac care, acute care and
home healthcare, energy efficient lighting solutions and new lighting
applications, as well as male shaving and grooming and oral healthcare.
News from Philips is located at www.philips.com/newscenter.

About apoplex medical technologies
apoplex medical technologies GmbH was founded in 2004 in Pirmasens, in the
west of the Rhineland-Palatinate, and, within the field of medical
technology, specializes in new and innovative technological products for
the prevention of strokes throughout the world. The subsidiary of Geratherm
Medical AG focuses on easily applicable and efficient methods of patient
screening using medical-technical applications to prevent strokes and
vascular dementia. The SRA (Stroke Risk Analysis) procedure is the first
practicable screening method for paroxysmal atrial fibrillation. It is
available in versions for use in medical practices and stroke units.
apoplex medical technologies is supported by an extensive academic and
clinical network, which professionally supplements its own core competences
in the fields of mathematics, physics and medicine. Further information is
available at www.apoplexmedical.com.

apoplex medical technologies GmbH
Albert Hirtz
Delaware Avenue 1 - 3
D-66953 Pirmasens
fon: +49/(0)6331/698998-0
fax: +49/(0)6331/698998-19
http://www.apoplexmedical.com
a.hirtz@apoplexmedical.com


End of Corporate News

---------------------------------------------------------------------

17.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------


Language:    English
Company:     Geratherm Medical AG
             Fahrenheitstraße 1
             98716 Geschwenda
             Germany
Phone:       +49 (0)36205 98-0
Fax:         +49 (0)36205 98-1 15
E-mail:      info@geratherm.com
Internet:    www.geratherm.com
ISIN:        DE0005495626
WKN:         549562
Listed:      Regulierter Markt in Frankfurt (Prime Standard);
             Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
             Stuttgart


End of News    DGAP News-Service
---------------------------------------------------------------------
221568 17.07.2013